Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Recommendation of “Moderate Buy” by Analysts
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the nineteen research firms that are covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating […]
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the nineteen research firms that are covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating […]